We are selling at the $3's now - hot money is not in this yet. I am in NEPH but if I wasn't I would be in this one. Did the HW - upside could be incredible on this.
Bottom line: At $3.25, the risk reward looks good - it's "RF blessed" for the biotech basket
Subscribe to:
Post Comments (Atom)
I bought at $.45 - and still am happy holder. After July 20th and a little calculation a price target of more than $100 seems realistic at a gains effect of Benlysta of 2.0 to 2.7 Billion a year (just for HGSI) - gets an annual profit per share of more than $11 - now calculate that by a moderate P/E ration of about 13... :)
ReplyDelete